Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Consensus Rating of "Buy" from Brokerages

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) have been assigned a consensus recommendation of "Buy" from the nine ratings firms that are presently covering the firm, Marketbeat.com reports. Eight analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $53.50.

ARCT has been the subject of several analyst reports. Scotiabank initiated coverage on shares of Arcturus Therapeutics in a research note on Wednesday, May 28th. They issued a "sector outperform" rating and a $32.00 price target for the company. Cantor Fitzgerald reissued an "overweight" rating on shares of Arcturus Therapeutics in a research note on Friday, March 7th. Canaccord Genuity Group lowered their price target on Arcturus Therapeutics from $68.00 to $66.00 and set a "buy" rating for the company in a report on Tuesday, May 13th. Wells Fargo & Company lowered their price target on Arcturus Therapeutics from $50.00 to $45.00 and set an "overweight" rating for the company in a report on Wednesday, May 14th. Finally, Wall Street Zen upgraded Arcturus Therapeutics from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd.

Institutional Trading of Arcturus Therapeutics

Several hedge funds have recently made changes to their positions in the business. Byrne Asset Management LLC grew its holdings in shares of Arcturus Therapeutics by 89.8% in the first quarter. Byrne Asset Management LLC now owns 2,885 shares of the biotechnology company's stock valued at $31,000 after purchasing an additional 1,365 shares in the last quarter. US Bancorp DE raised its position in Arcturus Therapeutics by 218.9% in the 1st quarter. US Bancorp DE now owns 3,393 shares of the biotechnology company's stock valued at $36,000 after purchasing an additional 2,329 shares in the last quarter. Virtus ETF Advisers LLC boosted its stake in shares of Arcturus Therapeutics by 38.8% in the 4th quarter. Virtus ETF Advisers LLC now owns 4,051 shares of the biotechnology company's stock valued at $69,000 after buying an additional 1,132 shares during the period. KLP Kapitalforvaltning AS acquired a new position in shares of Arcturus Therapeutics during the fourth quarter worth about $71,000. Finally, GAMMA Investing LLC grew its position in shares of Arcturus Therapeutics by 3,482.9% during the first quarter. GAMMA Investing LLC now owns 5,231 shares of the biotechnology company's stock worth $550,000 after buying an additional 5,085 shares in the last quarter. Institutional investors and hedge funds own 94.54% of the company's stock.

Arcturus Therapeutics Price Performance

NASDAQ ARCT traded down $0.06 during trading hours on Wednesday, hitting $12.29. 645,432 shares of the company's stock traded hands, compared to its average volume of 426,349. Arcturus Therapeutics has a 52-week low of $8.04 and a 52-week high of $28.05. The company has a market capitalization of $333.30 million, a PE ratio of -4.86 and a beta of 2.30. The company has a debt-to-equity ratio of 0.06, a current ratio of 5.64 and a quick ratio of 5.64. The firm's 50-day moving average is $12.05 and its 200-day moving average is $14.24.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last issued its earnings results on Monday, May 12th. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.58) by $1.06. The company had revenue of $29.38 million during the quarter, compared to analysts' expectations of $25.64 million. Arcturus Therapeutics had a negative return on equity of 27.41% and a negative net margin of 47.47%. Equities analysts forecast that Arcturus Therapeutics will post -2.22 EPS for the current fiscal year.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.